美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

bioAffinity Technologies Equity Warrants Exp 23 June 2027 Warrant

0.1402

0.0000

成交量：- -

成交額：- -

市值：399.13萬

市盈率：-0.01

高：0.1402

開：0.1402

低：0.1402

收：0.1402

52周最高：0.8121

52周最低：0.0101

股本：2,846.86萬

流通股本：2,846.86萬

量比：- -

換手率：- -

股息：- -

股息率：- -

每股收益(TTM):-20.7379

淨資產收益率：-622.65%

總資產收益率：-107.12%

市淨率：1.09

市盈率(LYR):- -

資料載入中...

總覽公司新聞公告

概念

no data

沒有相關數據

資金流向

資金流入：

資金流出：

新聞

bioAffinity Technologies 宣佈獲墨西哥專利許可，涵蓋基於Cypath® Lung技術的新型肺癌檢測方法

bioAffinity Technologies宣佈旗艦肺癌診斷產品Cypath® Lung在2025年創下營收與銷量新紀錄

bioAffinity Technologies啓動其非侵入性Cypath®肺癌診斷技術的大規模縱向臨床研究

bioAffinity Technologies攜手布魯克陸軍醫療中心啓動驗證研究，拓展Cypath® Lung無創肺癌早篩檢測的樣本採集選項

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/BIAFW"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BIAFW","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BIAFW\",,,,,undefined,":{"symbol":"BIAFW","market":"US","secType":"STK","nameCN":"bioAffinity Technologies Equity Warrants Exp 23 June 2027 Warrant","latestPrice":0.1402,"timestamp":1782331200000,"preClose":0.1402,"halted":0,"volume":0,"delay":0,"changeRate":0,"floatShares":28468614,"shares":28468614,"eps":-20.7379,"marketStatus":"已收盤","change":0,"latestTime":"06-24 16:00:00 EDT","open":0.1402,"high":0.1402,"low":0.1402,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-20.7379,"tradingStatus":0,"nextMarketStatus":{"tag":"盤前交易","tradingStatus":1,"beginTime":1782374400000},"marketStatusCode":5,"adr":0,"listingDate":1662004800000,"exchange":"NASDAQ","adjPreClose":0.1402,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BIAFW\",,,,,undefined,":{"symbol":"BIAFW","floatShares":28468614,"roa":"-107.12%","roe":"-622.65%","lyrEps":0,"shares":28468614,"dividePrice":0,"high":0.1402,"amplitude":0,"preClose":0.1402,"low":0.1402,"week52Low":0.0101,"pbRate":"1.09","psRate":"0.71","week52High":0.8121,"institutionHeld":0,"latestPrice":0.1402,"eps":-20.7379,"divideRate":0,"volume":0,"delay":0,"ttmEps":-20.7379,"open":0.1402,"prevYearClose":0.35,"prevWeekClose":0.1402,"prevMonthClose":0.0101,"prevQuarterClose":0.4525,"fiveDayClose":0.1566,"twentyDayClose":0.18,"sixtyDayClose":0.4625},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/BIAFW\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-08-14","symbol":"BIAFW","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"盤前","type":"earning","dateTimestamp":1755144000000,"reportTimeType":"pre","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"BIAFW\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"BIAFW\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BIAFW\",pageSize:4,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1188716872","title":"bioAffinity Technologies 宣佈獲墨西哥專利許可，涵蓋基於Cypath® Lung技術的新型肺癌檢測方法","url":"https://stock-news.laohu8.com/highlight/detail?id=1188716872","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1188716872?lang=zh_tw&edition=fundamental","pubTime":"2026-05-27 20:00","pubTimestamp":1779883242,"startTime":"0","endTime":"0","summary":"bioAffinity Technologies, Inc. 近日宣布，其利用Cypath® Lung技术的新型肺癌检测方法已获得墨西哥专利许可通知。\n这项专利授权覆盖了公司创新的肺癌检测技术，进一步巩固了其在癌症早期诊断领域的知识产权布局。Cypath® Lung技术旨在通过非侵入性方法，提升肺癌检测的准确性与可及性。\n此次获得墨西哥专利许可，标志着该技术在全球范围内的知识产权保护取得又一重要进展。它为bioAffinity Technologies未来在墨西哥及更广泛拉丁美洲市场的商业拓展奠定了坚实基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BIAF","BIAFW","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1134036435","title":"bioAffinity Technologies宣佈旗艦肺癌診斷產品Cypath® Lung在2025年創下營收與銷量新紀錄","url":"https://stock-news.laohu8.com/highlight/detail?id=1134036435","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1134036435?lang=zh_tw&edition=fundamental","pubTime":"2026-03-13 20:02","pubTimestamp":1773403339,"startTime":"0","endTime":"0","summary":"bioAffinity Technologies公司今日公布，其旗舰产品——肺癌诊断方案Cypath® Lung在2025年实现了创纪录的营收表现与单位销量。这一里程碑标志着该诊断工具在市场上的强劲增长和广泛认可。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BIAF","BK4139","BIAFW"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1158495268","title":"bioAffinity Technologies啓動其非侵入性Cypath®肺癌診斷技術的大規模縱向臨床研究","url":"https://stock-news.laohu8.com/highlight/detail?id=1158495268","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1158495268?lang=zh_tw&edition=fundamental","pubTime":"2026-03-10 19:49","pubTimestamp":1773143344,"startTime":"0","endTime":"0","summary":"bioAffinity Technologies公司宣布，已启动一项针对其非侵入性Cypath®肺癌诊断技术的大规模纵向临床研究。该研究旨在通过长期跟踪和数据收集，进一步验证该诊断方法的有效性与可靠性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BIAFW","BK4139","BIAF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1186193545","title":"bioAffinity Technologies攜手布魯克陸軍醫療中心啓動驗證研究，拓展Cypath® Lung無創肺癌早篩檢測的樣本採集選項","url":"https://stock-news.laohu8.com/highlight/detail?id=1186193545","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1186193545?lang=zh_tw&edition=fundamental","pubTime":"2026-02-25 21:32","pubTimestamp":1772026320,"startTime":"0","endTime":"0","summary":"生物亲和技术公司（bioAffinity Technologies）宣布，将与布鲁克陆军医疗中心（Brooke Army Medical Center）合作开展一项验证研究，旨在扩大其Cypath® Lung无创早期肺癌检测技术的样本采集方式。此项研究将评估不同样本采集方案的有效性，以提升该检测技术的可及性和应用便利性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BIAF","BIAFW"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":4,"totalPage":1,"pageCount":1,"totalSize":4,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/BIAFW\",params:#limit:6,delay:false,,,undefined,":[]}}